The transcription factor C/EBPa (CEBPA) is a key player in granulopoiesis and leukemogenesis. We have previously reported the interaction of C/EBPa with other proteins (utilizing mass spectrometry) in transcriptional regulation. In the present study, we characterized the association of the MYST domain histone acetyltransferase Tat-interactive protein (TIP) 60 (HTA-TIP) with C/EBPa. We show in pull-down and co-precipitation experiments that C/EBPa and HTATIP interact. A chromatin immunoprecipitation (ChIP) and a confirmatory Re-ChIP assay revealed in vivo occupancy of the C/EBPa and GCSF-R promoter by HTATIP. Reporter gene assays showed that HTATIP is a coactivator of C/EBPa. The co-activator function of HTATIP is dependent on its intact histone acetyltransferase (HAT) domain and on the C/EBPa DNA-binding domain. The resulting balance between histone acetylation and deacetylation at the C/EBPa promoter might represent an important mechanism of C/EBPa action. We observed a lower expression of HTATIP mRNA in undifferentiated U937 cells compared to retinoic acid-induced differentiated U937 cells, and correlated expression of CEBPA and HTATIP mRNA levels were observed in leukemia samples. These findings point to a functional synergism between C/EBPa and HTATIP in myeloid differentiation and suggest that HTATIP might be an important player in leukemogenesis.
Introduction
Transcription factors strongly influence cellular lineage commitment during hematopoiesis, and the enforced expression of some transcription factors can alter the fate of developing hematopoietic progenitor cells. 1 The CCAAT/enhancer-binding protein alpha (C/EBPa, CEBPA) is a tissue-specific transcription factor expressed in the liver, differentiating adipocytes and myelomonocytic cells that was shown to regulate hematopoietic activity.
2,3 C/EBPa-knockout mice have a block in granulocyte differentiation in the fetal liver and in newborns. 4 C/EBPa acts as a tumor suppressor gene in acute myeloid leukemia (AML). 5 Inactivation of C/EBPa is an important event in AML and overexpression of C/EBPa leads to differentiation and growth arrest in AML. 6 Thus, C/EBPa has essential functions in the regulation of cell proliferation and differentiation. Recent data from our laboratory indicated that the differentiation and proliferation functions of C/EBPa involve direct protein-protein interactions. [7] [8] [9] [10] Furthermore, C/EBPa is known to cooperate with the histone acetyltransferases (HATs) p300 and CREBbinding protein (CBP) to activate transcription. 11, 12 Thus, C/EBPa functions within a large network consisting of different protein-protein interactions to regulate gene expression and hence cellular differentiation by maintaining a fine balance between histone acetylation and deacetylation. However, in-depth studies involving protein-protein interactions of C/EBPa with HATs are lacking. 11, 13 In our efforts to identify interacting partners of C/EBPa utilizing mass spectrometry-based proteomics, 7, 8 we identified TIP60 (HTATIP; Tat-interactive protein, 60 kDa), a MYST family HAT. The identification of TIP60 as a C/EBPa interacting partner is intriguing because of the role of TIP60 in transcriptional activation, DNA repair and histone acetylation. TIP60 functions as a co-activator of many key cellular proteins such as nuclear hormone receptors, b-catenin and nuclear factor-kB. 14 In the present study, we provide evidence for the physical association of TIP60 with C/EBPa and the consequences of this association for the transcriptional function of C/EBPa, and for the correlated expression between C/EBPa and TIP60 in certain subtypes of leukemia and during differentiation of U937 cell line. Our data might provide a useful framework for elucidating the role of TIP60 in the biology of leukemia in general and in novel C/EBPa functions in particular.
Materials and methods

Cell culture, plasmids and reporter constructs
The HEK293T, U937 and K562 C/EBPa-ER (estrogen receptor) cell lines were cultured as described previously. 7 The pEYFP (yellow fluorescent protein)-N1-TIP60 and pEYFP-N1-TIP60 (-HAT) plasmids have been described. 15 TIP60 was subcloned from pcDNA3-TIP60 to obtain the pGEX-4T3-TIP60 (GST-TIP60) expression plasmid. The pcDNA3-C/EBPa, pcDNA6-C/EBPaHis 6 , pTK, p(C/EBP)2TK, pGAL4-luc and pGAL4DBD-VP16 plasmids were described previously. 7, 9 As an internal control plasmid for co-transfection assays, the pRL-TK (thymidine kinase) construct driving a Renilla luciferase gene (Promega, Madison, WI, USA) was used. The C/EBPa-GAL4DBD expression plasmid was kindly provided by A Friedman. GST, GST-C/ EBPa and GST-C/EBPa DBD (the basic region and the leucine zipper of C/EBPa; amino acid 270-358, fused to GST) plasmids were kind gifts from C Nerlov. GST-C/EBPa 1-97 (fragment containing transactivation domain 1) and GST-C/EBPa 98-262 (fragment containing transactivation domain 2) of C/EBPa were constructed by PCR amplification from C/EBPa-His 6 and cloned into the EcoRI/XhoI sites of pGEX4 T.1 (Amersham Biosciences, GE Healthcare, Uppsala, Sweden). Details of plasmid construction are available upon request.
Reporter gene assays
Reporter assays using transient transfection of 293T cells have been described before. 7 The DNA amount of the reporter constructs and expression plasmids used for transfections were 0.1 mg for pTK, p(CEBP)2TK and pGAL4-luc; 0.01 mg for pRL-TK; 0.1 mg for the expression plasmids for C/EBPa and 0.05, 0.1, 0.2 or 0.3 mg for pEYFP-N1-TIP60 (or pcDNA3-TIP60) or pEYFP-N1-TIP60(-HAT) and 0.1, 0.2 or 0.3 mg for C/EBPa-GAL4DBD. The total DNA amount of pre-transfection was normalized with the corresponding empty expression vectors.
Glutathione S-transferase pull down, gel electrophoresis and mass spectrometry
The proteomics methodology was used essentially as described recently by our group. 7, 8 The separation of peptides by onedimensional nano reverse-phase liquid chromatography and their identification by matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF/TOF), including the use of the GPS Explorer software for protein identification, were performed as described. 16 
Co-precipitation
293T cells were transfected with expression plasmids for YFP-TIP60, YFP-EV (empty vector) and His 6 -tagged C/EBPa as described. 17 For co-immunoprecipitation, nuclear extracts were prepared from 293T cells transfected with C/EBPa and YFP-TIP60 expression plasmids and were used for pull down with antibodies against TIP60 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; sc-5725 (N terminal) and sc-5727 (C terminal), 1 mg each, mixed together). The protocol used for co-immunoprecipitation was described before. 8 The following antibodies were used for subsequent immunodetection: rabbit anti-C/EBPa polyclonal antibody (sc-61; Santa Cruz), rabbit anti-green fluorescent protein (GFP) monoclonal antibody (Invitrogen, Molecular Probes, Karlsruhe, Germany) and mouse anti-His 6 (1 922 416, Roche, Indianapolis, IN, USA).
Chromatin immunoprecipitation (ChIP) assay, Re-ChIP, real-time PCR quantification of genomic DNA ChIP, cell sorting, semiquantitative reverse transcriptase-PCR and expression analysis of HTATIP/CEBPA in leukemia samples are described in detail in the Supplementary Information.
Results
Proteomic identification of TIP60 as an interacting partner of C/EBPa
We have previously reported the use of mass spectrometry-based proteomics in identifying C/EBPa-interacting proteins in vitro as well as in vivo. 7, 8 In the present study, we extended our approach to include full-length C/EBPa. A glutathione S-transferase (GST) C/EBPa fusion protein was used to pull down C/EBPa-interacting proteins from nuclear extracts of the myeloid cell line U937 prepared under similar experimental conditions as described previously 7 ( Supplementary Figure 1a) . Protein spots specific for the GST-C/EBPa pull down ( Figure 1a) were excised from the gels and identified by MALDI-TOF/TOF. Additionally, pre-purified GST pull-down samples (pre-cleared with GST protein) were incubated with the GST-C/EBPa bait and subjected to 12% SDS-polyacrylamide gel electrophoresis (PAGE) followed by nano reverse-phase liquid chromatography and subsequent peptide identification by MALDI-TOF/TOF (Figure 1b) . Twentynine candidate interacting proteins were identified using these approaches (Supplementary Table 1 ). No major overlap was found among the proteins identified by the two approaches used, probably reflecting the differences in the separation techniques used and the fact that only a subset of potential interactors was identified by either approach. However, confirming the validity of these approaches several known C/EBPa interacting partners, such as pRB (retinoblastoma susceptibility protein), hnRNP, E2F4 and C/EBPa itself, were among the proteins identified.
TIP60 was identified as one of the interacting partners of C/EBPa. Because of its function as a HAT involved in many biological processes, we chose to concentrate on the analysis of the TIP60-C/EBPa interaction.
Confirmation of C/EBPa and TIP60 interaction
To confirm the interaction of TIP60 with C/EBPa, we performed co-precipitation and GST pull-down assays. The GST-TIP60 fusion protein was able to retain in vitro-translated [ Figure 1b) . Confocal microscopy also revealed colocalization of TIP60 and C/EBPa in the nucleus (data not shown). Taken together, these experiments showed that C/EBPa and TIP60 do interact, confirming the result of the proteomic interaction screen.
TIP60 increases the ability of C/EBPa to transactivate a minimal TK promoter
To test the ability of TIP60 to modulate C/EBPa-mediated transcriptional activation, transient transfection assays were performed in the HEK293T cell line using a luciferase reporter plasmid with a minimal TK promoter containing two CCAAT sites. 8 Co-transfection of a TIP60 expression construct enhanced the ability of C/EBPa to transactivate the reporter plasmid fivefold compared to C/EBPa alone in a dose-dependent manner ( Figure 2c ). In control experiments, no effect of TIP60 on C/EBPa activity was observed when a reporter plasmid without CCAAT sites was used. TIP60 alone had no effect on luciferase activity, indicating that TIP60 specifically mediates upregulation of the reporter through its interaction with C/EBPa.
HAT activity of TIP60 is required for its cooperativity with C/EBPa
We next investigated whether the HAT activity of TIP60 is required to increase the transcriptional activation capacity of C/EBPa. While YFP-TIP60 co-transfected with C/EBPa is able to increase the luciferase activity fivefold compared to C/EBPa alone, co-transfection of the YFP-TIP60(-HAT) expression plasmid failed to affect the transactivation capacity of C/EBPa (Figure 2d ). YFP-TIP60 and YFP-TIP60(-HAT) were expressed at equal levels ( Figure 2e ). Furthermore, we show that co-transfection of C/EBPa with TIP60 does not alter the C/EBPa protein levels to rule out an increase in the reporter gene activity due to increased C/EBPa protein levels (Figure 2f ).
Co-activation by TIP60 depends on the DNA-binding domain of C/EBPa on a GAL4-responsive promoter
The DNA-binding domain (DBD) of C/EBPa is required for its transactivation potential. 18 To investigate whether the TIP60-mediated increase in the transactivation capacity of C/EBPa requires the DBD of C/EBPa, a C/EBPa-Gal4DBD construct was used, in which the DBD of C/EBPa is replaced by the Gal4-DBD. C/EBPa-Gal4DBD transactivates a Gal4-UAS 5 (pentameric upstream-activating sequence) luciferase reporter plasmid 35-fold (Figure 3a) . However, co-transfection of TIP60 did not lead to increased transactivation. Gal4DBD-VP16 was used as a positive control in these experiments. These results indicate that the co-activator function of TIP60 requires the C/EBPa-DBD.
To investigate the protein domains involved in the C/EBPa-TIP60 interaction, we performed GST pull-down experiments using GST-tagged C/EBPa DBD and C/EBPa 1-97. 293T cells were transfected with pcDNA-TIP60 and 24 h after transfection, nuclear extracts were incubated with the GST-tagged proteins as shown in Figure 3b (upper panel). Immunoblot analysis using TIP60 antibody revealed that TIP60 interacts with GST-C/EBPa, GST-C/EBPa DBD and GST-C/EBPa 1-97. Equal amounts of GST-tagged proteins were used in these experiments (Figure 3b , lower panel, Supplementary Figure 1c) . Taken together, we conclude that both the DBD and the fragment containing the transactivation domain of C/EBPa are sufficient on their own for interaction with TIP60.
TIP60 occupies the endogenous C/EBPa and GCSFR promoters in vivo
We next investigated whether the C/EBPa-TIP60 interaction also occurs in vivo at the C/EBPa promoter and the GCSFR promoter, which is known to be a target of C/EBPa. 19, 20 To address this, we performed quantitative radioactive and non-radioactive ChIP experiments in K562 cells that express conditionally active C/EBPa-ER chimaera (Figure 4 ). These cells undergo granulocytic differentiation when treated with b-estradiol (data not Figure 1 Mass spectrometry-based proteomics identifies putative proteins of the C/EBPa multiprotein complex. (a) Silver-stained two-dimensional gel showing differentially expressed proteins after glutathione S-transferase (GST) pull down from nuclear extracts of U937; protein spots that were excised and subsequently analyzed by mass spectrometry are marked with arrows. (b) Coomassie-stained SDS-polyacrylamide gel electrophoresis (PAGE) gels after GST pull down from U937 nuclear extracts using GST-C/EBPa. Nuclear extracts were pre-cleared thrice by incubation with GST protein that retained all the proteins unspecifically interacting with both matrix and the GST protein. The pre-cleared extract was then incubated with the GST-C/EBPa bait. After several wash steps to remove unbound proteins, the complex components were eluted from the beads, separated by two-dimensional SDS-PAGE and stained with colloidal Coomassie; proteins identified are listed in Supplementary Table 1. shown). Antibodies against TIP60 and C/EBPa were used to precipitate the crosslinked chromatin. Our results showed that even in the uninduced condition (0 h) some endogenous TIP60 and C/EBPa are present at the C/EBPa promoter (Figures 4a and  b) . After induction with b-estradiol, immunoprecipitation with anti-TIP60 antibodies (N/C terminal) led to a strong enrichment of the GCSFR promoter amplicon and a significant enrichment for the CEBPA promoter amplicon (Figure 4a ). Immunoprecipitation using the C/EBPa antibody led to stronger amplification of the GCSFR and CEBPA promoter amplicons (Figure 4b ). The Figure 1d) . Thus, C/EBPa and TIP60 associate in vivo in the context of chromatin and are more abundant on the C/EBPa promoter when cells are induced toward granulocytic differentiation.
Differentiation induction leads to increased histone acetylation at the C/EBPa and GCSFR promoters in vivo concomitant with TIP60 recruitment
Our results indicated TIP60 occupancy at the C/EBPa promoter. Therefore, we hypothesized that histone acetylation at the C/EBPa promoter might be influenced by TIP60 recruitment to chromatin. We therefore performed a ChIP experiment using antibodies against acetylated histones H3 and H4 to precipitate the crosslinked chromatin derived from uninduced and induced K562 C/EBPa-ER cells. As measured by quantitative PCR, abundant levels of acetylated H4 and H3 histones were found to be present at the C/EBPa and GCSFR promoter loci in K562 C/EBPa-ER cells 6 h after the addition of b-estradiol (Figures  4c and d) . Immunoprecipitation using an isotype-matched immunoglobulin G was also used to serve as a negative control (data not shown).
To verify the TIP60-C/EBPa interaction at the GCSFR promoter amplicon, a Re-ChIP experiment was performed. After b-estradiol treatment, crosslinked nuclear lysates were first immunoprecipitated with anti-C/EBPa, and then the immunoprecipitate was subjected to a second immunoprecipitation with anti-TIP60 antibodies. The amount of GCSFR promoter DNA was then assayed by quantitative real-time PCR. The second immunoprecipitation showed an enrichment of over 100-fold of the GCSFR promoter compared to the uninduced samples (Figure 4e ). This clearly shows a strong increase of TIP60 at the GCSFR promoter when the cells are induced toward granulocytic differentiation. In summary, we conclude that TIP60 might play an important role in the regulation of histone acetylation and deacetylation at the C/EBPa promoter.
HTATIP and CEBPA expression levels correlate in retinoic acid-induced myeloid differentiation in U937 cells as well as in certain leukemia subtypes
To analyze the level of TIP60 mRNA upon granulocytic differentiation, we used the myelomonocytic U937 cell line that can be induced to differentiate toward more mature granulocyte cells by retinoic acid treatment as assessed by the expression of the cell surface differentiation marker CD11b and morphology (data not shown). TIP60 expression was analyzed by a semiquantitative reverse transcriptase-PCR assay on RNA isolated from differentiated CD11b þ U937 cells by fluorescence-activated cell sorting after 60 h of treatment with retinoic acid. Compared to undifferentiated CD11b À U937 cells, higher TIP60 mRNA expression was observed in differentiated U937 cells. As expected, C/EBPa and C/EBPe transcript levels were increased upon myeloid differentiation. b-actin levels were used for RNA quality control (Figure 5a) .
To obtain a preliminary assessment whether this correlated expression would also be found in myeloid leukemias, we analyzed the mRNA expression of TIP60 and CEBPA in a microarray data set from a small cohort of patients with defined leukemia subtypes (CML: chronic myeloid leukemia; AML_M2: AML-M2 with the AML1/ETO fusion; AML_M3: AML-M3 with the PML/RARA fusion; AML_M4: AML-M4eo with the CBFB/ MYH11 fusion) and from normal bone marrow samples (Figure 5b) . A Pearson's two-tailed correlation analysis showed that there was a significant positive correlation between the expression levels of HTATIP and CEBPA when considering all samples (n ¼ 50) together (r ¼ 0.606, P ¼ 0.00000314). In view of the low sample number (n ¼ 10) in the individual subgroups, this correlation reached significance at the 95% confidence interval only in the group with the AML1/ETO fusion gene (AML_M2) (r ¼ 0.703, P ¼ 0.023). Studies in larger patient cohorts are expected to clarify this issue. HTATIP is a co-activator of CEBPA D Bararia et al
Discussion
Protein-protein interactions play key roles in all cellular processes and functions. Identifying and characterizing such protein interactions is therefore required to understand these processes at a molecular level. To our knowledge, TIP60 is the first MYST domain family member identified as an interaction partner of C/EBPa. This finding might be of potential importance with regard to the functions of C/EBPa, in particular since there are sparse data regarding C/EBPa and histone acetylation. While we were partially successful in finding known C/EBPa interaction partners using different proteomic approaches (twodimensional gels vs SDS-PAGE LC-MS/MS), we also identified several novel putative C/EBPa-interacting proteins, thereby giving new dimensions to C/EBPa functions. Future technological advances in the proteomics field should overcome the discrepancies found with the different proteomic approaches. Nevertheless, we report several additional putative C/EBPainteracting proteins to be characterized in future studies (Supplementary Table 1 ).
The TIP60-C/EBPa interaction is intriguing given the fact that TIP60 is a MYST domain HAT. This family of HATs has been linked to mediate long-lasting epigenetic changes of chromatin (for example, mof in Drosophila is responsible for X chromosome dosage compensation 21 ). Additionally, the acetyl transferase activity of TIP60 on nucleosomal histones in the presence of other factors has been reported, and TIP60 can function both as a transcriptional co-activator or as a co-repressor, connecting a number of different factors to the basal transcriptional machinery. 14 Thus, it is possible that upregulation of TIP60 in leukemia confers to the leukemic clone a survival advantage. It should be noted that TIP60 and two other MYST domain HATs (MOZ and MORF) have been shown to interact with other leukemia-relevant proteins like ETV6 15, 22 or to participate in leukemia-associated chromosomal translocations (for example, the MOZ/TIF2, MOZ/P300 and MORF/ CBP). 23 It was recently shown that TIP60 acts as a tumor suppressor gene in a mouse model. 24 However, we are unaware of any reports of chromosomal aberrations or mutations that directly target TIP60.
Interestingly, we observed that TIP60 can interact with the DBD as well as with the transactivation domain containing portions of C/EBPa (aa 1-97, Figure 3b ; and aa 98-262, data not shown). These fragments contain transactivation domains of C/EBPa. Thus, TIP60 could be an important transcriptional co-regulator for C/EBPa functions by acting in large multiprotein complexes with other factors that also associate with C/EBPa. This might be particularly true for proteins such as E2F, which have been shown to interact with both TIP60 25 and C/EBPa.
26
TIP60 can directly acetylate and stabilize non-histone proteins.
14 Our efforts to detect acetylation of C/EBPa by TIP60 failed (data not shown). The fact that C/EBPa and TIP60 are recruited to the C/EBPa and GCSFR promoters during granulocytic differentiation in vivo under physiological conditions ( Figure 4) suggests that TIP60 enhances the transactivation capacity of C/EBPa on these promoters. This has been reported for MYC. 27 It is possible that the primary targets of TIP60 acetylation in this context are the histones at C/EBPa-dependent genes. In fact, we show that there is increased histone acetylation when the cells are induced toward granulocytic differentiation concomitant with recruitment of C/EBPa and TIP60 at the GCSFR promoter. However, at the moment it is not clear whether histone acetylation is a prerequisite or a consequence of the C/EBPa-TIP60 interaction or whether this histone acetylation is a direct result of the TIP60 HAT activity.
The increase in expression of both C/EBPa and TIP60 during retinoic acid-induced differentiation of U937 cells suggests a role for TIP60 in myeloid differentiation. Expression microarray data from patients with defined leukemia subtypes showed an overall significant positive correlation between TIP60 (HTATIP) and C/EBPa mRNA levels (Figure 5b ), suggesting the role of TIP60 in leukemogenesis. However, the different levels of TIP60 expression in the AML subtypes could also be a reflection of the differentiation status of the AML blasts rather than being important for leukemogenesis. Nevertheless, TIP60 might be critical in regulating the promoters of myeloid differentiationspecific genes.
In summary, our observations and findings indicate a functional synergism between two tumor suppressor proteins involved in hematological malignancy. TIP60 may be an integral part of multiprotein complexes, which convert the transcriptional decisions initiated by C/EBPa into long-lasting epigenetic chromatin changes. Finally, our data provide a framework for investigating the mechanisms and signaling pathways that control the interaction of TIP60 with C/EBPa, for example, by examining the phenotype of mice with tissuespecific knockouts of these two genes.
